PT005 MDI Dose Ranging versus Foradil Aerolizer Study

Study identifier:PT005003

ClinicalTrials.gov identifier:NCT01349868

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients with Moderate to Severe COPD, Compared with Foradil® Aerolizer® (12 and 24 µg Open-Label) as Active Controls

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®)

Sex

All

Actual Enrollment

50

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 01 May 2011
Primary Completion Date: 01 Jul 2011
Study Completion Date: 01 Jul 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2016 by Pearl Therapeutics, Inc.

Sponsors

Pearl Therapeutics, Inc.

Collaborators

-

Inclusion and exclusion criteria